Literature DB >> 8664059

Vinorelbine/5-FU combination in metastatic breast cancer chemotherapy. A retrospective study of 63 cases.

L Cany, C Toulouse, A Ravaud, M Durand, L Mauriac.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8664059     DOI： 10.1016/0959-8049(95)00590-0

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  4 in total

Review 1.  Breast cancer therapies in development. A review of their pharmacology and clinical potential.

Authors:  D de Valeriola; A Awada; J A Roy; A Di Leo; L Biganzoli; M Piccart
Journal:  Drugs       Date:  1997-09       Impact factor: 9.546

2.  Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure.

Authors:  J Bonneterre; H Roché; A Monnier; J P Guastalla; M Namer; P Fargeot; S Assadourian
Journal:  Br J Cancer       Date:  2002-11-18       Impact factor: 7.640

3.  Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells: major implications for the detection of partly deficient patients.

Authors:  A B Van Kuilenburg; H van Lenthe; M J Blom; E P Mul; A H Van Gennip
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

4.  Capecitabine and vinorelbine in patients with metastatic breast cancer previously treated with anthracycline and taxane.

Authors:  Jin-Hee Ahn; Sung-Bae Kim; Tae-Won Kim; Sei-Hyun Ahn; Sun-Mi Kim; Jeong-Mi Park; Jung-Shin Lee; Yoon-Koo Kang; Woo Kun Kim
Journal:  J Korean Med Sci       Date:  2004-08       Impact factor: 2.153
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.